Cancer Res Treat.  2004 Apr;36(2):100-102.

Prospect of Anticancer Therapy

• Park HS

Abstract

No abstract available.

Reference

1. Savage DG, Antman KH. Imatinib mesylate-A new oral targeted therapy. N Engl J Med. 2002; 346:683–693. PMID: 11870247.

2. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003; 21:1637–1647. PMID: 12668652.

3. Druker BJ, Lydon NB. Lessons learned from the development of an abl thyrosine kinase inhibitor for chronic myelogenrus leukemia. J Clin Invest. 2000; 105:3–7. PMID: 10619854.

4. Herbst RS, Hong WK. Targeted therapy against the epidermal growth factor receptor. Semin Onco. 2002; 29:1–69.

5. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997; 3:2703–2707. PMID: 10068277.

6. Cohen-Jonathan E, Muschel RJ, McKenna WG, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res. 2000; 154:125–132. PMID: 10931682.

7. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol. 2000; 18(21 Suppl):54S–59S. PMID: 11060328.

8. Herbst Rs, Maddox AM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002; 20:3815–3825. PMID: 12228201.

9. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockade of vascular endothelial growth factor stress response increase the antitumor effect of ionizing radiation. Cancer Res. 1999; 59:3374–3378. PMID: 10416597.

10. Hidalgo M, Eckhardt SG. Development of matrix metalloprotease inhibitors in cancer therapy. J Natl Cancer Inst. 2001; 93:178–193. PMID: 11158186.

11. Harris CC, Hollstein M. Clinical implication of the p53 tumor-suppressor gene. N Engl J Med. 1993; 329:1318–1327. PMID: 8413413.

12. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R, Minna JD. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 1992; 52:2340–2343. PMID: 1559236.

13. Deisseroth AB, Pizzorno G. The use of chemotherapy resistance in cancer treatment. Cancer J Sci Am. 1997; 3:60–69. PMID: 9099453.

14. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Nat Cancer Inst. 1998; 90:273–286. PMID: 9486813.

15. Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB. Recent advances in the application of gene therapy to human disease. Am J Med. 1995; 99:537–552. PMID: 7485213.

16. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998; 18:180–183. PMID: 9462752.